ストックスクリーナーアプリを入手
0.00
100.00%
-13.85
アフターアワーズ：
14.19
14.19
+
Faeth Therapeutics Inc (SNSE) 最新ニュース
Sensei Biotherapeutics, Inc. will Change its Ticker to FTH from SNSE - marketscreener.com
SNSE Reiterates by BTIG -- Price Target Maintained at $55.00 - GuruFocus
Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics - TradingView
Sensei Biotherapeutics, Inc. has Changed its Name to Faeth Therapeutics, Inc - marketscreener.com
Sensei Biotherapeutics, Inc. Appoints Brian Stephenson as Chief Financial Officer, Effective June 12, 2026 - marketscreener.com
Faeth Therapeutics (FTH) Transitions from Sensei Biotherapeutics (SNSE) - GuruFocus
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership - TipRanks
Sensei Biotherapeutics changes name to Faeth Therapeutics - Investing.com
Sensei Biotherapeutics changes name to Faeth Therapeutics By Investing.com - Investing.com Canada
Faeth Therapeutics (SNSE) adopts FTH ticker, installs new CEO and CFO - Stock Titan
Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer - Business Wire
[EFFECT] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) president awarded 220,000 stock options at $29.89 - Stock Titan
Sensei Biotherapeutics grants director 12,500 options | SNSE Insider Trading - Stock Titan
Sensei Biotherapeutics (SNSE) director receives stock options on 12,500 shares - Stock Titan
Sensei Biotherapeutics (SNSE) Surges Over 20%: Key Levels to Watch After Strong RallyCovered Call Trade - newsline.com
SNSE Q1 2026 Earnings: Massive EPS Miss and Revenue Absence Highlight Clinical-Stage ChallengesEarnings Growth Analysis - newsline.com
SNSE Initiates Coverage by BTIG -- Price Target Announced at $55 - GuruFocus
Citi Maintains Sensei Biotherapeutics(SNSE.US) With Buy Rating, Maintains Target Price $55 - Moomoo
BTIG Research Initiates Coverage on Sensei Biotherapeutics With Buy Rating, $55 Price Target - marketscreener.com
BTIG Initiates Sensei Biotherapeutics(SNSE.US) With Buy Rating, Announces Target Price $55 - Moomoo
This Daktronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Sensei Biotherapeutics Overhauls Capital Structure at 2026 Meeting - TipRanks
Sensei Biotherapeutics (SNSE) registers 24.87M resale shares after Faeth deal - Stock Titan
Sensei Biotherapeutics (NASDAQ: SNSE) approves big share increase and new equity plans - Stock Titan
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
SNSE Q1 2026 Earnings: Massive EPS Miss Deepens Investor Concerns as Pre‑Revenue Biotech Faces HeadwindsAnnual Report - newsline.com
SNSE SEC FilingsSensei Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Millennium Management LLC Reduces Stake in Sensei Biotherapeutics Inc - GuruFocus
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 4, 2026 - BioSpace
Cantor Fitzgerald Maintains Sensei Biotherapeutics(SNSE.US) With Buy Rating - Moomoo
Cantor Fitzgerald reiterates Sensei Biotherapeutics stock rating By Investing.com - Investing.com Canada
Millennium-led group reports 3.1% stake in Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
Most and least shorted healthcare stocks with market cap up to $2B at the end of May - Seeking Alpha
Sensei Biotherapeutics | SCHEDULE 13G/A: Others - Moomoo
Sensei Biotherapeutics, Inc. 2025 Annual Report: Cancer Therapeutics Pipeline, Regulatory Strategy, and Intellectual Property Overview - Minichart
Sensei Biotherapeutics (SNSE) revises 10-K to reflect Faeth deal, PIKTOR focus and $200M financing - Stock Titan
Sensei Biotherapeutics to register 24.9M shares after Faeth deal (SNSE) - Stock Titan
Cambrian BioPharma sells $500,542 of Sensei Biotherapeutics stock - Investing.com India
Cambrian BioPharma sells $500,542 of Sensei Biotherapeutics stock By Investing.com - Investing.com Australia
Insider Sell: Biopharma Cambrian Reduces Stake in Sensei Biother - GuruFocus
Dual Insider Moves Shake Up Sensei Biotherapeutics Investor Watch - TipRanks
Insider Sell: Biopharma Cambrian Reduces Stake in Sensei Biotherapeutics Inc (SNSE) - GuruFocus
Sensei Biotherapeutics ten percent owner James Peyer sells $500k in stock - Investing.com
Sensei Biotherapeutics Insiders Sold Shares Worth Over $1.0M - TradingView
Cambrian BioPharma sells 25,000 Sensei Biotherapeutics (SNSE) shares - Stock Titan
Ten percent owner of Sensei Biotherapeutics (SNSE) sells 25,000 shares in open market - Stock Titan
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars - RTTNews
SNSE Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald Initiates Sensei Biotherapeutics at Overweight - marketscreener.com
SNSE PE Ratio & Valuation, Is SNSE Overvalued - Intellectia AI
SNSE Initiated Coverage by Lucid Capital Markets -- Rating Set t - GuruFocus
Lucid Capital Markets initiates Sensei Biotherapeutics stock with buy - Investing.com
Lucid Capital Markets initiates Sensei Biotherapeutics stock with buy By Investing.com - Investing.com Canada
SNSE Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageManagement Guidance Update - newsline.com
Sensei Biotherapeutics (SNSE) Slides 7.4% as Selling Pressure Builds Near Support LevelsMotive Wave - The Legal Advocate
Sensei Biotherapeutics Inc. (SNSE) Edges Higher: Key Levels and Volume Analysis After a Modest UptickDividend Arbitrage - The Legal Advocate
Sensei Biotherapeutics Inc. (SNSE) Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D Investment and Pre-Revenue StatusEarnings Risk Report - The Legal Advocate
SNSE Q1 2026 Earnings: EPS Significantly Below Estimates as Company Invests in PipelineCommunity Buy Signals - Newser
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):